| NAMN | nicotinic acid mononucleotide |
|---|---|
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| CR | calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio... |
| CRL | cell repository line; Certified Record Librarian; complement receptor location; complement receptor ... |
| cholinergic agonists | Drugs that bind to and activate cholinergic receptors. (12 Dec 1998) |
|---|---|
| cholinergic antagonists | Drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. (12 Dec 1998) |
| cholinergic blockade | Inhibition by a drug of nerve impulse transmission at autonomic ganglionic synapses (ganglionic blockade), at postganglionic parasympathetic effector cells (e.g., by atropine), and at myoneural junctions (myoneural blockade), the inhibition of a cholinergic agent. (05 Mar 2000) |
| cholinergic fibres | Nerve fibres liberating acetylcholine at the synapse after an impulse. (12 Dec 1998) |
| cholinergic medication | <pharmacology> Medications which stimulate cholinergic receptors (for example bethanechol). (15 Jan 1998) |
| cholinergic neuron | <physiology> Neurons in which actylcholine is the neurotransmitter. (15 Jan 1998) |
| cholinergic parasympathomimetic agent | <pharmacology> A chemical substance that causes the release of choline (acetylcholine) from parasympathetic nerve endings. (15 Jan 1998) |
| cholinergic receptors | Chemical sites in effector cells or at synapses through which acetylcholine exerts its action. (05 Mar 2000) |
| cholinergic system | <physiology> The system of nerve cells that uses acetylcholine as its neurotransmitter, nerve cells in the cholinergic system are damaged in the brains of Alzheimer patients. (15 Jan 1998) |
| cholinergic urticaria | A form of physical or non-allergic urticaria initiated by heat (e.g., hot baths, physical exercise, pyrexia, exposure to sun or to a warm room) or by excitement; the rather distinctive lesions consist of pruritic areas 1 to 2 mm in diameter surrounded by bright red macules. Synonym: heat urticaria. (05 Mar 2000) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |